IATI Biomed 2016: OrbiMed launches $307m fund for Israeli med-tech investmentsMay. 24, 2016
On the eve of a major event highlighting Israel’s accomplishments in the medical technology industry, international healthcare venture capital venture firm OrbiMed announced Monday the closing of its second Israel-focused venture capital fund.
The fund, OrbiMed Israel Partners II, saw subscribers committing approximately $307 million. Investors include several of the world’s largest healthcare companies in addition to dozens of institutional investors and family offices.
OrbiMed is the world’s biggest VC investor dedicated exclusively to the healthcare sector, with over $15 billion in assets under management, investing in a wide array of companies through a range of vehicles – private equity funds, public equity funds, royalty/debt funds, and others. The firm started its activities in Israel in 2010, with the establishment of the OrbiMed Israel Partners fund, which closed at $222 million in 2011.
“Israel is a compelling locus of life sciences innovation, on par with top regions in the US and Europe,” commented Jonathan Silverstein, co-head of OrbiMed’s global private equity effort. “With this fund we will further accelerate our investment pace in Israel and help nurture local innovations into leading healthcare companies.”
How compelling a locus it is was on display in Tel Aviv on Tuesday, as the 15th annual IATI-Biomed Conference got underway.